Prognostic and Predictive Markers, and Stratifications Tables, for the Detection and Treatment of Renal Cell Carcinoma

2019 ◽  
pp. 511-528
Author(s):  
Helen Davis Bondarenko ◽  
Raisa S. Pompe ◽  
Emanuele Zaffuto ◽  
Shahrokh F. Shariat ◽  
Pierre I. Karakiewicz
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Predictive Markers ◽  
Prognostic And Predictive Markers

Prognostic and Predictive Markers, and Stratifications Tables, for the Detection and Treatment of Renal Cell Carcinoma

2017 ◽  
pp. 1-17 ◽  
Author(s):  
Helen Davis Bondarenko ◽  
Raisa S. Pompe ◽  
Emanuele Zaffuto ◽  
Shahrokh F. Shariat ◽  
Pierre I. Karakiewicz
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Predictive Markers ◽  
Prognostic And Predictive Markers

scholarly journals Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma

2013 ◽  
Vol 31 (7) ◽  
pp. 971-972 ◽  
Author(s):  
Muhammad A. Khattak ◽  
Farrah Bakr ◽  
Marcin Krzystanek ◽  
Zoltan Szallasi ◽  
Marco Gerlinger ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Predictive Markers ◽  
Prognostic And Predictive Markers

scholarly journals Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma

2020 ◽  
Vol 9 (1) ◽  
pp. 1846901
Author(s):  
Christopher Montemagno ◽  
Anais Hagege ◽  
Delphine Borchiellini ◽  
Brice Thamphya ◽  
Olivia Rastoin ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Predictive Markers ◽  
Cell Renal Cell Carcinoma ◽  
Prognostic And Predictive Markers

Predictive Markers in Advanced Renal Cell Carcinoma

2013 ◽  
Vol 40 (4) ◽  
pp. 459-464 ◽  
Author(s):  
M. Dror Michaelson ◽  
Walter M. Stadler
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Predictive Markers ◽  
Advanced Renal Cell Carcinoma

Body Mass Index, Sarcopenia and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma

Oncology ◽  
2021 ◽  
Author(s):  
Tressie Herrmann ◽  
Cécile Mione ◽  
Pierre-François Montoriol ◽  
Ioana Molnar ◽  
Angeline Ginzac ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Weight Gain ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Checkpoint Inhibitors ◽  
Predictive Markers ◽  
Skeletal Muscle Index ◽  
Weight Variation ◽  
The Impact

Introduction : The advent of immune checkpoint inhibitors (ICI) such as nivolumab has enabled outcomes for metastatic renal cell carcinoma (mRCC) to be improved. Although, only around 25% of patients respond to these therapies without being able to formally identify them. Datas on relevant predictive markers are still laking. The obesity paradox has been shown as a relevant prognostic marker in mRCC with better outcomes for obese patients. Nevertheless, the impact of weight variation and the presence of sarcopenia during ICI is not known for now. Methods : In a retrospective study, weight and its variations were collected at first day of ICI and at 6 weeks of treatment. Scanographic imagery was used to define the skeletal muscle index (SMI) as a reflect of sarcopenia. The impact of these parameters as predictive and prognostic factors for mRCC with nivolumab was evaluated. Results : A higher BMI at baseline was significantly associated with response at the first scan (p=0.036). Longer OS was observed for patients with a weight gain compared to the group with weight loss (p=0.00028). Median OS for sarcopenic patients was 17.2 months, and 31.6 months for the non-sarcopenic group of patients, but there was no statistical difference. Conclusion : This trial showed that a higher BMI and weight gain during nivolumab treatment were good predictive markers for outcomes in mRCC with nivolumab. Sarcopenia and variations in SMI could thus be of interest, but further studies are required.

scholarly journals Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

Oncotarget ◽  
2017 ◽  
Vol 8 (18) ◽  
pp. 30410-30421 ◽  
Author(s):  
Javier Puente ◽  
Nuria Laínez ◽  
Marta Dueñas ◽  
María José Méndez-Vidal ◽  
Emilio Esteban ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Predictive Markers ◽  
Cell Renal Cell Carcinoma

scholarly journals Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Arancha Cebrián ◽  
Teresa Gómez del Pulgar ◽  
María José Méndez-Vidal ◽  
María Luisa Gonzálvez ◽  
Nuria Lainez ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Predictive Markers ◽  
First Line
Sign in / Sign up

Export Citation Format

Share Document